The Food and Drug Administration has been cracking down on a class of constipation drugs because of fears around potential cardiovascular risks. This additional regulatory oversight has big implications for a drug still in the pipeline from Nektar Therapeutics (NASDAQ:NKTR), and it brought the company's shares down 14% on Monday. In this video, Motley Fool health care analyst Brenton Flynn talks about the market for these drugs, and how the FDA's concerns are impacting not only Nektar but several other companies operating in this space.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/28/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.